Viela reports detailed Phase II/III data for rare CNS disorder therapy

Viela touted a potential dosing advantage and reiterated its plans to submit mid-year a BLA to FDA for inebilizumab to treat neuromyelitis optica spectrum disorder (NMOSD). The update came during a presentation at AAN on Tuesday in which the company reported detailed data from the Phase II/III N-MOmentum trial

Read the full 493 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE